Taken together, bsAb CD73xEpCAM may be useful to devise an alternate and more tumor-selective immunotherapeutic approach to overcome the CD73-mediated immunosuppression in patients with EpCAM-overexpressing refractory OC. Here, NT5E is linked to neoplasm.